DDX41 and neoplasm: The Ab–peptide epitope conjugates that were designed to release CMVp495–503 coated tumor cells with CMV-pMHCI for recognition by CMVp-CTLs, resulting in delayed tumor growth in mouse models, particularly when combined with immune checkpoint-blocking Abs [9].